Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

- Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT® pancreatic data at a premier international gastroenterology conference -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mon, 18 May 2026 16:01:00 -0400

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -

- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -

Alpha Tau to Participate in May Investor Conferences

Mon, 18 May 2026 08:30:00 -0400

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026.

Event:
Event:
Event:
Event:
Event:
Event:
Event:
Event:
Event:
Event:	- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One associated grade 3 serious adverse event (SAE) was observed, since resolved - - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months - - Conference call with principal investigator to be held today, Monday, May 11, 2026, at 8:30am ET

StreetInsider.com News Articles

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences